PMID- 31879067
OWN - NLM
STAT- MEDLINE
DCOM- 20210715
LR  - 20210715
IS  - 1715-3360 (Electronic)
IS  - 0008-4182 (Linking)
VI  - 55
IP  - 3
DP  - 2020 Jun
TI  - Polypoidal choroidal vasculopathy in Canada.
PG  - 199-211
LID - S0008-4182(19)30555-1 [pii]
LID - 10.1016/j.jcjo.2019.10.011 [doi]
AB  - Polypoidal choroidal vasculopathy (PCV) is an exudative age-related macular 
      degeneration (AMD) subtype found more frequently among Asians than Caucasians. If 
      untreated, it may lead to severe vision loss. PCV appears to be frequently 
      underdiagnosed in Canada, although misdiagnosis of PCV as AMD carries the risk of 
      inadequate treatment and unsatisfactory clinical outcomes. Diagnosis can be made 
      on the basis of multimodal imaging, including optical coherence tomography (OCT) 
      and OCT angiography combined with colour fundus photography, or by other imaging 
      techniques; the gold-standard indocyanine green angiography (ICGA) is not widely 
      used in Canada. Treatment involves anti-vascular endothelial growth factor 
      (anti-VEGF) agents (bevacizumab, ranibizumab, or aflibercept), alone or in 
      combination with photodynamic therapy (PDT). Recent clinical trials have shown 
      that ranibizumab in combination with PDT is superior to ranibizumab monotherapy 
      (EVEREST II), and aflibercept monotherapy is as effective in patients meeting PDT 
      rescue criteria as aflibercept combined with rescue PDT (PLANET). It appears that 
      most Canadian PCV patients are treated with anti-VEGF monotherapy, with or 
      without PDT.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Lam, Wai-Ching
AU  - Lam WC
AD  - Department of Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong; 
      Department of Ophthalmology and Vision Sciences, University of Toronto, Unity 
      Health Toronto, St. Michael's Hospital, Toronto, Ont.. Electronic address: 
      waichlam@hku.hk.
FAU - Choudhry, Netan
AU  - Choudhry N
AD  - Vitreous Retina Macula Specialists of Toronto, Toronto, Ont.
FAU - Wong, David
AU  - Wong D
AD  - Department of Ophthalmology and Vision Sciences, University of Toronto, Unity 
      Health Toronto, St. Michael's Hospital, Toronto, Ont.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191224
PL  - England
TA  - Can J Ophthalmol
JT  - Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
JID - 0045312
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Canada
MH  - Choroid
MH  - *Choroid Diseases/drug therapy
MH  - Fluorescein Angiography
MH  - Humans
MH  - Intravitreal Injections
MH  - *Photochemotherapy
MH  - Ranibizumab/therapeutic use
MH  - Tomography, Optical Coherence
MH  - Vascular Endothelial Growth Factor A
EDAT- 2019/12/28 06:00
MHDA- 2021/07/16 06:00
CRDT- 2019/12/28 06:00
PHST- 2019/05/21 00:00 [received]
PHST- 2019/10/06 00:00 [revised]
PHST- 2019/10/15 00:00 [accepted]
PHST- 2019/12/28 06:00 [pubmed]
PHST- 2021/07/16 06:00 [medline]
PHST- 2019/12/28 06:00 [entrez]
AID - S0008-4182(19)30555-1 [pii]
AID - 10.1016/j.jcjo.2019.10.011 [doi]
PST - ppublish
SO  - Can J Ophthalmol. 2020 Jun;55(3):199-211. doi: 10.1016/j.jcjo.2019.10.011. Epub 
      2019 Dec 24.